TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15818076

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 1703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1703

Group type: COMPARATOR
Intervention: Nonselective nonsteroidal anti‐inflammatory drug
Number of subjects: 1703
Study: 11910256

Group type: EXPERIMENTAL
Intervention: Thioridazine (200 mg, bid)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Risperidone (3 mg, bid)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Haloperidol (7.5 mg, bid)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All three coadministered therapies
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy transitioning to coadministration
Number of subjects: 36
Study: 11122797

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthracyclines, platinum compounds, and paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunohistochemical determination of tumor receptor status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-HER2/neu monoclonal antibody
Number of subjects: 0
Study: 8669350

Group type: EXPERIMENTAL
Intervention: Hospital-at-Home (HAH) rehabilitation team
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional discharge (CD) preparation
Number of subjects: 60
Study: 2354058

Group type: EXPERIMENTAL
Intervention: Maze test measuring path length traced in 1 minute
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Maze test
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Visual analogue sedation scale
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative maze scores
Number of subjects: 50
Study: 683909

Group type: EXPERIMENTAL
Intervention: Extra potassium supplements
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 49
Study: 30786793

Group type: EXPERIMENTAL
Intervention: 24% sucrose solution
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 29056520

Group type: EXPERIMENTAL
Intervention: LPS 0.5 ng/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LPS 1 ng/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LPS 2 ng/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27001804

Group type: EXPERIMENTAL
Intervention: Single oral dose of PXVX0200 (approximately 5 × 10(8) CFU)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 24647737

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.i.d.)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 36
Study: 22699130

Group type: EXPERIMENTAL
Intervention: Low-frequency TENS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 20
Study: 20829597

Group type: EXPERIMENTAL
Intervention: Local thermal stimulation of the paraumbilical region for 20 min at a temperature of 40 °C (Group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Herbal medicine Daikenchuto (TJ‐100; 5.0 g) with distilled water (Group B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Distilled water alone (Group C)
Number of subjects: 28
Study: 17079360

Group type: EXPERIMENTAL
Intervention: Goldenseal (3210 mg daily for 14 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Kava kava (1227 mg daily for 14 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rifampin (600 mg daily for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clarithromycin (1000 mg daily for 7 days)
Number of subjects: 20
Study: 16244024

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion via 2 epidural catheters for postoperative analgesia (group E)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intraoperative general anesthesia and postoperative IV morphine analgesia (group G)
Number of subjects: 30
Study: 12107602

Group type: EXPERIMENTAL
Intervention: valsartan 80 mg daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: atenolol 50 mg daily
Number of subjects: 110
Study: 10338217

Group type: EXPERIMENTAL
Intervention: Oral glutamine (GLN) 10 g three times daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Glycine-control (GLY) 10 g three times daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Oral glutamine (GLN)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Glycine-control (GLY)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Oral and parenteral glutamine (GLN)
Number of subjects: 66
Study: 8747034

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1903079

Group type: EXPERIMENTAL
Intervention: Dihydroergocryptine (DEK) at mean daily doses of approximately 40 mg (ranging from 15 to 60 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7381028

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (200 mg orally three times a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31725021

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 60
Study: 30426214

Group type: EXPERIMENTAL
Intervention: 6-month intervention including education and support to reduce intakes of fat and total calories
Number of subjects: 578

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 578
Study: 28671933

Group type: EXPERIMENTAL
Intervention: 1-km treadmill walking test
Number of subjects: 50
Study: 25640616

Group type: EXPERIMENTAL
Intervention: Dental endoscopy‐assisted training program
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Calibration training
Number of subjects: 6
Study: 24556530

Group type: COMPARATOR
Intervention: TBP condition in POD (n=41)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TBP condition in mPOD (n=49)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TBP+mobile group in mPOD (n=47)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mobile users for podcasts
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Twitter mobile app users
Number of subjects: 90
Study: 21785889

Group type: EXPERIMENTAL
Intervention: Seminar
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: CD
Number of subjects: 648

Group type: COMPARATOR
Intervention: Comparison group (untrained)
Number of subjects: 648
Study: 19540659

Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound (LIPUS) treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study: 17440643

Group type: EXPERIMENTAL
Intervention: Losartan (L) 50 mg plus Hydrochlorothiazide (HCTZ) 12.5 mg titrated to L 100 mg plus HCTZ 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan (L) and Hydrochlorothiazide (HCTZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stepped-care (HCTZ 12.5 mg plus Atenolol 50 mg)
Number of subjects: 0
Study: 15239726

Group type: EXPERIMENTAL
Intervention: Serum mast cell tryptase measurement
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Serial tryptase measurement
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of tryptase and histamine measurements
Number of subjects: 64
Study: 12185869

Group type: EXPERIMENTAL
Intervention: Mechanical suture with closed technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual suture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mechanical suture with open technique
Number of subjects: 100
Study: 9627939

Group type: EXPERIMENTAL
Intervention: Vaccination against pertussis
Number of subjects: 16500

Group type: EXPERIMENTAL
Intervention: Vaccination against measles
Number of subjects: 16500

Group type: EXPERIMENTAL
Intervention: Vaccination against rubella
Number of subjects: 16500

Group type: EXPERIMENTAL
Intervention: Vaccination against mumps
Number of subjects: 16500

Group type: EXPERIMENTAL
Intervention: Rubini strain vaccination
Number of subjects: 16500
Study: 8250765

Group type: EXPERIMENTAL
Intervention: Buserelin (900 micrograms/d administered intranasally)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Danazol (400 mg/d p.o.)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Buserelin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 19
Study: 3533825

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (2.5 mg) + 573 mg potassium chloride 3 times a day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31788880

Group type: EXPERIMENTAL
Intervention: nano-curcumin (80 mg daily for 8 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 30588501

Group type: EXPERIMENTAL
Intervention: DCGAN-created brain MR images
Number of subjects: 63

Group type: COMPARATOR
Intervention: Real brain MR images
Number of subjects: 63
Study: 27694598

Group type: EXPERIMENTAL
Intervention: Closed splinting for type I fractures
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Operative treatment for type III fractures
Number of subjects: 81

Group type: COMPARATOR
Intervention: Normal age- and gender-matched individuals (control group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Type III fractures
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 81
Study: 24567202

Group type: EXPERIMENTAL
Intervention: Diabetes report card with letter grades (A to F)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Report card with face reflecting glycemic control
Number of subjects: 177

Group type: COMPARATOR
Intervention: Standard report card with A1C value
Number of subjects: 177
Study: 22189524

Group type: EXPERIMENTAL
Intervention: Clindamycin or first-generation cephalosporin (IV for 2-4 days, then oral)
Number of subjects: 199
Study: 20965458

Group type: EXPERIMENTAL
Intervention: Same-day home discharge with bolus-only abciximab regimen
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Overnight hospitalization with 12-hour abciximab infusion
Number of subjects: 1005
Study: 17410124

Group type: EXPERIMENTAL
Intervention: BIBT986
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15818530

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11939978

Group type: EXPERIMENTAL
Intervention: Psychopharmacologic intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pretreatment phase
Number of subjects: 0
Study: 9440419

Group type: EXPERIMENTAL
Intervention: Concentric (CON) training of the left quadriceps femoris (QF) for nine weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) assessment of cross-sectional area and spin-spin relaxation time (T2) of each QF before and 3 days after the ECC exercise bout
Number of subjects: 9
Study: 7545721

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2205994

Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group without cerclage
Number of subjects: 160
Study: 7215419

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 11
Study: 30789515

Group type: EXPERIMENTAL
Intervention: Sequential application of 1,450-nm diode laser and 450-nm blue light
Number of subjects: 24

Group type: COMPARATOR
Intervention: 450-nm blue light alone
Number of subjects: 24
Study: 28301865

Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manual therapy and static ultrasound
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Manual therapy and diadynamic currents
Number of subjects: 60
Study: 25794691

Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma (PRP) during myringoplasty
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no PRP) during myringoplasty
Number of subjects: 64
Study: 23723343

Group type: EXPERIMENTAL
Intervention: Provent
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Placebo Provent
Number of subjects: 67

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 67
Study: 20551220

Group type: COMPARATOR
Intervention: Varenicline (0.25, 0.5, 1.0, 2.0 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Varenicline (0.5 or 1.0 mg) twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19214045

Group type: EXPERIMENTAL
Intervention: Contextual stigma reduction program
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Control stigma reduction program
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Biomedical stigma reduction program
Number of subjects: 86

Group type: COMPARATOR
Intervention: No-program control
Number of subjects: 86
Study: 17255304

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib (compared to placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sorafenib (in combination with IFN, bevacizumab, or temsirolimus)
Number of subjects: 0
Study: 15124757

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 30 mcg IM once weekly
Number of subjects: 608

Group type: COMPARATOR
Intervention: IFNbeta‐1a 60 mcg IM once weekly
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Both doses of IFNbeta‐1a
Number of subjects: 608
Study: 11697022

Group type: EXPERIMENTAL
Intervention: Allicin-containing garlic supplement, one capsule daily for 12 weeks
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 9561285

Group type: EXPERIMENTAL
Intervention: Performance 1 (P1; 55 mEq Na+, 365 mOsm.kg H2O-1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AstroAde (AA; 164 mEq Na+, 253 mOsm.kg-1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AA/P1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: P1/P1, P2/P1, P2G/P1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0/P1
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0/0
Number of subjects: 6
Study: 7898227

Group type: EXPERIMENTAL
Intervention: LDL apheresis plus simvastatin 40 mg daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Colestipol 20 g plus simvastatin 40 mg daily
Number of subjects: 39
Study: 2803775

Group type: EXPERIMENTAL
Intervention: Topical fusidic acid 1%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Topical chloramphenicol 0.5%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Subconjunctival cephazolin
Number of subjects: 80
Study: 1100301

Group type: EXPERIMENTAL
Intervention: Penfluridol (30, 60, and 120 mg weekly)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Penfluridol
Number of subjects: 22
Study: 31389909

Group type: COMPARATOR
Intervention: Statins (10 mg of rosuvastatin)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo + Exercise Training (PLET)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Statins + Exercise Training (STAET)
Number of subjects: 83
Study: 28255102

Group type: EXPERIMENTAL
Intervention: Triple-Antiplatelet Therapy (TAPT) with cilostazol
Number of subjects: 133

Group type: COMPARATOR
Intervention: Dual-Antiplatelet Therapy (DAPT) (aspirin and clopidogrel)
Number of subjects: 133
Study: 26638888

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 44
Study: 23414490

Group type: EXPERIMENTAL
Intervention: Higher IL-6 concentration
Number of subjects: 5653

Group type: EXPERIMENTAL
Intervention: IL-6 -174 CC genotype
Number of subjects: 5653
Study: 21150649

Group type: EXPERIMENTAL
Intervention: 3-day weighed food records
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Standardized training for dietitians
Number of subjects: 1368
Study: 20074436

Group type: EXPERIMENTAL
Intervention: Phytothermotherapy at the thermal resort of Garniga Terme (Trento, Italy)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (26 patients)
Number of subjects: 56
Study: 17071020

Group type: EXPERIMENTAL
Intervention: Bi-weekly judicial status hearings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard schedule of court hearings
Number of subjects: 0
Study: 15139484

Group type: EXPERIMENTAL
Intervention: Dilatation with a 54‐F Savary dilator
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Four quadrant incisions with a needle knife
Number of subjects: 11
Study: 11323010

Group type: EXPERIMENTAL
Intervention: Impedance plethysmography (IPG)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Contrast venography (CV)
Number of subjects: 324
Study: 9348677

Group type: EXPERIMENTAL
Intervention: Foreign speech
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pink noise
Number of subjects: 72

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Retest after four weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Internal consistency measure
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Original error rates
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Self-report measures of noise susceptibility
Number of subjects: 72
Study: 2890900

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerosis (ES) plus cimetidine
Number of subjects: 113

Group type: COMPARATOR
Intervention: Cimetidine alone (Control)
Number of subjects: 113
Study: 29930373

Group type: EXPERIMENTAL
Intervention: Insignia customised orthodontic system
Number of subjects: 174

Group type: COMPARATOR
Intervention: Damon Q noncustomised orthodontic system
Number of subjects: 174
Study: 27707442

Group type: EXPERIMENTAL
Intervention: Nasal Dilator Strip (NDS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 26
Study: 26051110

Group type: EXPERIMENTAL
Intervention: Weekly 35 mg risedronate
Number of subjects: 290

Group type: COMPARATOR
Intervention: Daily 5 mg risedronate
Number of subjects: 290
Study: 23677653

Group type: COMPARATOR
Intervention: Daily injections of filgrastim (100 μg/m(2))
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: DA‐3031 3.6 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: DA‐3031 6 mg
Number of subjects: 61
Study: 21596879

Group type: EXPERIMENTAL
Intervention: Fospropofol IV infusion with a bolus and increased infusion rate for agitation events (infusion/bolus)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fospropofol IV infusion with an increased infusion rate for agitation events (infusion only)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol IV infusion with an increased infusion rate for agitation events
Number of subjects: 60
Study: 19565403

Group type: EXPERIMENTAL
Intervention: Tonsillectomy (n=33)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Partial tonsillectomy (tonsillotomy) (n=34)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (n=76)
Number of subjects: 67
Study: 17040924

Group type: EXPERIMENTAL
Intervention: Behavioural intervention involving training of network leaders to counsel their social network members on risk prevention
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 286
Study: 12780882

Group type: EXPERIMENTAL
Intervention: Gentamicin fleece plus primary closure (Genta Group)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Open treatment alone (Open Group)
Number of subjects: 103
Study: 10853884

Group type: EXPERIMENTAL
Intervention: propofol 6% SAZN
Number of subjects: 24

Group type: COMPARATOR
Intervention: propofol 1% SAZN
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diprivan-10
Number of subjects: 24
Study: 8883120

Group type: EXPERIMENTAL
Intervention: Daily oral alendronate
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Radiographic absorptiometry (RA) of the phalanges
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Single‐energy X‐ray absorptiometry (SXA)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Dual‐energy X‐ray absorptiometry (DXA)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Duplicate measurements
Number of subjects: 1609

Group type: COMPARATOR
Intervention: Healthy premenopausal women (reference group)
Number of subjects: 1609
Study: 1595914

Group type: EXPERIMENTAL
Intervention: Intraarticular bupivacaine (0.25%, with or without 1:200,000 epinephrine)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (0.03%, with or without 1:200,000 epinephrine)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 139
Study: 6392164

Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 50

Group type: COMPARATOR
Intervention: Renografin‐76
Number of subjects: 50
Study: 29984565

Group type: EXPERIMENTAL
Intervention: Aerobic exercise and high-intensity respiratory muscle training (24 supervised sessions, 3 per week, 8 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual post-operative care
Number of subjects: 37
Study: 27209505

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2) or Cisplatin (75 mg/m2) plus Tirapazamine with concurrent radiation therapy (70 Gy over 7 weeks)
Number of subjects: 200
Study: 26871969

Group type: EXPERIMENTAL
Intervention: Continuous exercise training (n=18)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Interval exercise training (n=17)
Number of subjects: 35
Study: 24638013

Group type: COMPARATOR
Intervention: Cisplatin plus pemetrexed (CP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg for 1 year
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall trial success rate
Number of subjects: 150
Study: 22610128

Group type: EXPERIMENTAL
Intervention: Hippotherapy simulator ON
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hippotherapy simulator ON (severely disabled group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Hippotherapy simulator OFF
Number of subjects: 38
Study: 19652234

Group type: EXPERIMENTAL
Intervention: Computed tomography-guided aspiration
Number of subjects: 841

Group type: COMPARATOR
Intervention: Key-hole approach
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 841